💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Metolazone

CHEMBL878 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
365.8 g/mol
LogP
4.1
Phase
4

This diuretic medication helps the kidneys remove excess salt and water from the body, lowering blood pressure and reducing fluid buildup. It is used in the management of heart failure and chronic kidney disease.

분자량

365.8000 g/mol

LogP

4.10

TPSA

101.00 Ų

리핀스키 5의 법칙

통과

치료 영역

Chronic Kidney Disease Hypertension Heart Failure Cardiovascular Disease

작용 기전

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C

                

                

                
                

                    
InChI

                    
InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H16ClN3O3S

                    

                    
                    

                        
HBD / HBA

                        
2 / 5

                    

                    
                    

                        
회전 가능 결합

                        
2

                    

                    
                    
                    

                        
무거운 원자

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
This diuretic medication helps the kidneys remove excess salt and water from the body, lowering blood pressure and reducing fluid buildup. It is used in the management of heart failure and chronic kidney disease.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Metolazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL878.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4170.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.